BidaskClub lowered shares of Sinovac Biotech (NASDAQ:SVA) from a strong-buy rating to a buy rating in a report published on Friday morning.
Shares of Sinovac Biotech stock traded down $0.02 during trading on Friday, reaching $8.16. The company’s stock had a trading volume of 10,470 shares, compared to its average volume of 26,869. Sinovac Biotech has a 12-month low of $4.60 and a 12-month high of $8.75.
Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Sinovac Biotech in the third quarter valued at approximately $163,000. Citadel Advisors LLC boosted its stake in shares of Sinovac Biotech by 189.8% in the third quarter. Citadel Advisors LLC now owns 34,193 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 22,393 shares in the last quarter. State Street Corp boosted its stake in shares of Sinovac Biotech by 18.5% in the second quarter. State Street Corp now owns 49,281 shares of the biopharmaceutical company’s stock valued at $333,000 after buying an additional 7,711 shares in the last quarter. Spark Investment Management LLC boosted its stake in shares of Sinovac Biotech by 271.3% in the fourth quarter. Spark Investment Management LLC now owns 66,100 shares of the biopharmaceutical company’s stock valued at $520,000 after buying an additional 48,300 shares in the last quarter. Finally, Eqis Capital Management Inc. boosted its stake in shares of Sinovac Biotech by 4.6% in the fourth quarter. Eqis Capital Management Inc. now owns 156,492 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 6,953 shares in the last quarter. Hedge funds and other institutional investors own 12.62% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Sinovac Biotech (SVA) Lowered to Buy at BidaskClub” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/14/sinovac-biotech-sva-lowered-to-buy-at-bidaskclub.html.
Sinovac Biotech Company Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.